Insider Trading March 27, 2026

Neuronetics Insider Purchases Total $211,000 as Company Posts Mixed Q4 Results

Ten percent owner Jorey Chernett increases stake amid low share price and recent leadership changes

By Marcus Reed STIM
Neuronetics Insider Purchases Total $211,000 as Company Posts Mixed Q4 Results
STIM

Jorey Chernett, who holds roughly a ten percent ownership stake in Neuronetics, Inc. (STIM), acquired an additional 150,000 shares of the company's common stock across two transactions on March 25-26, 2026, for a combined cost of $211,000. The purchases occurred as the stock traded near $1.45, close to its 52-week low, and follow a quarter that produced revenue growth but missed on earnings per share. After the transactions, Chernett holds 8,893,276 shares directly.

Key Points

  • Jorey Chernett, a ten percent owner, bought 150,000 Neuronetics shares on March 25-26, 2026, for a total of $211,000.
  • After the transactions Chernett directly holds 8,893,276 shares; Neuronetics has a market cap of $92.97 million.
  • Neuronetics reported Q4 2025 revenue of $41.8 million (2.73% above estimates) but EPS of -$0.10 missed the -$0.09 forecast; Canaccord cut its price target to $3.00 from $7.00 while keeping a Buy rating, and Dan Reuvers was named CEO.

Insider buying in Neuronetics, Inc. (STIM) continued late in March when Jorey Chernett, identified as a ten percent owner of the company, purchased additional common shares, according to a Form 4 filing with the Securities and Exchange Commission.

The filing shows that on March 25, 2026, Chernett acquired 125,000 shares in a single transaction at prices ranging between $1.38 and $1.42, for an aggregate reported cost of $175,000. The following day, March 26, 2026, Chernett purchased another 25,000 shares at $1.44 each, adding $36,000 to the total outlay. Combined, the two trades amount to $211,000 and 150,000 newly acquired shares.

Following these purchases, the filing reports Chernett directly owns 8,893,276 shares of Neuronetics. The company’s market capitalization is reported at $92.97 million.

The insider activity occurred while the stock was changing hands near $1.45 per share and close to its 52-week low of $0.80. Platform data cited in public filings indicate the shares have fallen about 8% over the past week and roughly 51% over the last six months. An available Fair Value analysis on the same platform suggests the shares are trading near fair value.


Recent operating and financial developments

Neuronetics released fourth-quarter 2025 results that showed revenue expansion but an earnings-per-share shortfall versus expectations. The company reported revenue of $41.8 million, topping the consensus projection of $40.66 million - a 2.73% positive surprise. On the bottom line, EPS was -$0.10, missing the forecasted -$0.09, which the company’s reported figures characterize as an 11.11% negative surprise.

In addition to the quarterly results, Canaccord has revised its price target on Neuronetics, reducing it from $7.00 to $3.00 while retaining a Buy rating on the shares. The firm noted that the fourth-quarter results and guidance aligned with expectations.

On the corporate leadership front, Neuronetics named Dan Reuvers as its new chief executive officer. The company also reported that its second quarter was operationally cash flow positive.


Context and implications

These insider purchases increase Chernett’s direct holding in the company and come amid a period of mixed operating signals: revenue growth alongside an EPS miss, a sharply lower price target from an analyst, and management changes. The combination of purchase activity and recent operational updates provides shareholders with additional data points on internal stakeholder behavior and company trajectory.

Risks

  • Share price volatility - The stock has declined about 8% over the past week and roughly 51% over six months, increasing short-term market risk for investors.
  • Earnings performance - The company missed EPS expectations in Q4 2025, which could affect near-term investor sentiment and analyst outlooks.
  • Analyst reassessment - A notable reduction in a price target (from $7.00 to $3.00) indicates differing views on valuation that may contribute to market uncertainty.

More from Insider Trading

Insider Buy: Jorey Chernett Adds $157,500 in Oncology Institute Stock Mar 27, 2026 Aflac director Charles D. Lake II disposes $536,365 in shares Mar 27, 2026 Yorktown Energy Partners Trims Ramaco Resources Stake, Sells $104,792 of METC Class B Shares Mar 26, 2026 Yorktown IX trims stake in Ramaco Resources, sells 9,207 Class B shares for $103k Mar 26, 2026 Ramaco Resources director disposes $5.82 million in shares over three days Mar 26, 2026